Wuxi, China, September 24, 2026
WuXi Biologics has announced that its drug substance and drug product manufacturing facilities at the Wuxi Mashan site successfully passed a two-week, unannounced U.S. Food and Drug Administration (FDA) GMP inspection, reinforcing the company’s regulatory compliance and commercial manufacturing capabilities. The inspection covered multiple FDA-approved biologic products, including monoclonal antibodies, bispecific antibodies, fusion proteins and enzyme products. The successful completion of the inspection represents another regulatory milestone for WuXi Biologics as it supports the commercial production and supply of biologic medicines for global pharmaceutical partners. According to the company, the result further demonstrates the robustness of its quality management system, GMP operations and integrated manufacturing capabilities. The Wuxi Mashan facility combines drug-substance and drug-product manufacturing at the same site, enabling the company to coordinate technology transfer, manufacturing scale-up and commercial supply activities.
FDA GMP Inspection Reinforces Manufacturing Quality
The latest FDA GMP inspection was conducted without advance notice and lasted two weeks, according to WuXi Biologics. The inspection evaluated manufacturing operations supporting several categories of FDA-approved biologics, including monoclonal antibodies, bispecific antibodies, fusion proteins and enzymes. Successfully completing such regulatory inspections is an important part of maintaining manufacturing operations for products supplied to regulated markets. WuXi Biologics said the outcome reinforces its adherence to FDA GMP requirements and its ability to support consistent commercial production. The company also highlighted the role of its quality systems and operational processes in maintaining manufacturing standards across its biologics network. For pharmaceutical partners, regulatory compliance and reliable manufacturing execution are important considerations when commercial products require ongoing supply to patients and healthcare systems.
Wuxi Mashan Supports Commercial Biologics Supply
The Wuxi Mashan site has an integrated manufacturing model covering both drug substance and drug product activities. WuXi Biologics said this structure supports the connection of technology transfer, production scale-up and commercial manufacturing, potentially improving coordination throughout the manufacturing process. The company identifies the Mashan facility as the first biopharmaceutical manufacturing site in China to receive both FDA and European Medicines Agency approval for commercial production. Over the past 13 years, the company says the site has achieved a 100% pass rate across more than 600 regulatory and customer audits and has supported the global launch of more than 20 biologic medicines. These figures are company-reported and reflect the site’s reported audit and commercial manufacturing history.
Advertisement
WuXi Biologics Reports Broad Quality Compliance
WuXi Biologics also reported broader regulatory and quality achievements across its global operations. As of June 30, 2026, the company said it had successfully completed 49 regulatory inspections, including 22 conducted by the FDA and EMA, and had secured 166 facility license approvals. In addition, WuXi Biologics reported more than 2,000 GMP quality audits conducted by global customers, including more than 280 audits by European Union Qualified Persons. The company’s global manufacturing network includes 26 drug-substance facilities and 19 drug-product facilities. These capabilities support WuXi Biologics’ role as a contract research, development and manufacturing organization (CRDMO) serving pharmaceutical and biotechnology companies developing and commercializing biologic medicines.
The successful FDA inspection at Wuxi Mashan adds another milestone to WuXi Biologics’ commercial manufacturing and quality-compliance record. While the announcement does not represent a new drug approval, it is relevant to the pharmaceutical manufacturing sector because FDA GMP inspections are an important component of regulatory oversight for facilities producing medicines for the U.S. market. The inspection covered facilities involved in manufacturing already FDA-approved biologic products, and WuXi Biologics said the outcome strengthens its ability to provide reliable commercial supply to partners. As demand for complex biologics continues to require specialized manufacturing capabilities, GMP compliance, quality systems and supply reliability remain important components of the global biopharmaceutical manufacturing ecosystem.
Source: WuXi Biologics press release
